Quoin Pharmaceuticals, Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Myers
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 42127 Pleasant Forest Court Ashburn VA United States of America 20148-7349
- IPO Date
- Aug 1, 2016
- CIK
- 0001671502
- Website
- quoinpharma.com
- Similar Companies
- Business
- Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company that develops and commercializes therapeutic products targeting rare and orphan diseases, including Netherton Syndrome, scleroderma, peeling skin syndrome, palmoplantar keratoderma, SAM syndrome, recessive dystrophic epidermolysis bullosa, microcystic lymphatic malformations and venous malformations. Founded in 2018 and headquartered in Ashburn, Virginia, the company was formerly known as Cellect Biotechnology Ltd and maintains an Israel-based heritage with operations focused primarily on the United States, Europe, Middle East and Japan through exclusive international marketing and distribution partnerships covering 60 countries. Its lead product candidate, QRX003, comprises a once-daily topical lotion with a broad-spectrum serine protease inhibitor formulated using proprietary Invisicare technology for Netherton Syndrome and SAM Syndrome, currently advancing in two active pivotal registrational clinical studies across the U.S., Europe and Middle East under an open U.S. Investigational New Drug application; QRX008 targets scleroderma; QRX009 addresses peeling skin syndrome and palmoplantar keratoderma; and additional programs including QRX004 for recessive dystrophic epidermolysis bullosa and topical rapamycin formulations at 4% lotion and 5% dermal patch loadings for microcystic lymphatic malformations and venous malformations. In October 2025, Quoin closed a private placement financing of up to $104.5 million with healthcare-focused investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diema Partners, Pine Capital and others, providing an initial $16.5 million upfront plus up to $88 million from warrant exercises to fund operations, research and development including QRX003 clinical completion, working capital and potential acquisitions through 2027; the European Medicines Agency granted Orphan Drug Designation for QRX003 in Netherton Syndrome, offering 10 years of market exclusivity upon approval; and in November 2025, the company achieved target rapamycin loadings with clinical batch manufacturing planned for Q4 2025 and trials starting in the first half of 2026, alongside appointing Sally Lawlor as CFO. Quoin launched the NETHERTON NOW campaign to raise awareness and support patients affected by Netherton Syndrome, holds a research agreement with Queensland University of Technology and a license agreement supporting its pipeline, and targets underserved patient populations with no current approved therapies through its innovative topical delivery platforms.
Company News
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals Stock Surges Friday: What's Happening?
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results